+

WO2003006672A3 - Anticorps d'acide nucleique antimicrobien, materiaux et procedes de fabrication et d'utilisation correspondants - Google Patents

Anticorps d'acide nucleique antimicrobien, materiaux et procedes de fabrication et d'utilisation correspondants Download PDF

Info

Publication number
WO2003006672A3
WO2003006672A3 PCT/US2002/021663 US0221663W WO03006672A3 WO 2003006672 A3 WO2003006672 A3 WO 2003006672A3 US 0221663 W US0221663 W US 0221663W WO 03006672 A3 WO03006672 A3 WO 03006672A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid antibodies
present
making
materials
Prior art date
Application number
PCT/US2002/021663
Other languages
English (en)
Other versions
WO2003006672A2 (fr
Inventor
David L Scott Jr
Original Assignee
Squared Biotechnologies Inc D
David L Scott Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squared Biotechnologies Inc D, David L Scott Jr filed Critical Squared Biotechnologies Inc D
Priority to AU2002316619A priority Critical patent/AU2002316619A1/en
Publication of WO2003006672A2 publication Critical patent/WO2003006672A2/fr
Publication of WO2003006672A3 publication Critical patent/WO2003006672A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à des procédés d'inhibition de la prolifération d'agents pathogènes entraînant des maladies. Plus particulièrement, l'invention se rapporte à des procédés de localisation et de récupération de polypeptides immunogéniques exposés en surface (SEIP) de microbes, tels que les bactéries, les champignons, et les protozoaires, qui sont impliqués dans l'adhésion de ces agents pathogènes à des surfaces de cellule hôte, et dans l'adhésion de molécules de fixation de fer à des surfaces de cellule pathogène. Par ailleurs, les SEP selon l'invention sont utilisés en tant que substrats afin d'obtenir des anticorps d'acide nucléique à affinité élevée. De tels anticorps d'acide nucléique à affinité élevée isolés sont ensuite utilisés pour lier les SEIP pathogènes afin d'inhiber la prolifération de l'agent pathogène. Ces anticorps d'acide nucléique selon l'invention sont par conséquent utiles dans la prévention, le diagnostic et le traitement des maladies et des infections pathogènes.
PCT/US2002/021663 2001-07-10 2002-07-10 Anticorps d'acide nucleique antimicrobien, materiaux et procedes de fabrication et d'utilisation correspondants WO2003006672A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002316619A AU2002316619A1 (en) 2001-07-10 2002-07-10 Antimicrobial nucleic acid antibodies, and materials and methods for making and using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30439001P 2001-07-10 2001-07-10
US60/304,390 2001-07-10

Publications (2)

Publication Number Publication Date
WO2003006672A2 WO2003006672A2 (fr) 2003-01-23
WO2003006672A3 true WO2003006672A3 (fr) 2007-11-22

Family

ID=23176314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021663 WO2003006672A2 (fr) 2001-07-10 2002-07-10 Anticorps d'acide nucleique antimicrobien, materiaux et procedes de fabrication et d'utilisation correspondants

Country Status (2)

Country Link
AU (1) AU2002316619A1 (fr)
WO (1) WO2003006672A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878302A (zh) * 2007-06-29 2010-11-03 明治制果株式会社 绿脓杆菌的外膜蛋白质pa4710
CN101138319B (zh) * 2007-09-28 2010-04-14 中国科学院华南植物园 星果藤的组织培养繁殖方法
US10900043B2 (en) 2014-09-02 2021-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating bacterial disease
WO2016036839A1 (fr) * 2014-09-02 2016-03-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et méthodes de traitement de la gonorrhée
EP4116316A1 (fr) 2015-07-04 2023-01-11 Evaxion Biotech A/S Protéines et acides nucléiques utiles dans des vaccins ciblant pseudomonas aeruginosa

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083843A2 (fr) * 2001-04-10 2002-10-24 D-Squared Biotechnologies, Inc. Polypeptides associes a la membrane externe
WO2003020875A2 (fr) * 2001-06-17 2003-03-13 D-Squared Biotechnologies, Inc. Polypeptides immunogenes a surfaces exposees aux staphylocoques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083843A2 (fr) * 2001-04-10 2002-10-24 D-Squared Biotechnologies, Inc. Polypeptides associes a la membrane externe
WO2003020875A2 (fr) * 2001-06-17 2003-03-13 D-Squared Biotechnologies, Inc. Polypeptides immunogenes a surfaces exposees aux staphylocoques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARENKAMP S.J.: "Cloning, Expression, and DNA Sequence Analysis of Genes Encoding Nontypeable Haemophilus infuenzae High-Molecular-Weight Surface-Exposed Proteins Related to Filamentous Hemagglutinin of Bordetella pertussis", INFECTION AND IMMUNITY, vol. 60, no. 4, April 1992 (1992-04-01), pages 1302 - 1313, XP000578343 *
GROEGER W.: "Transmembrane topology of the two FhuB domains representing the hydrophobic components of bacterial ABC transporters involved in the uptake of siderophores, haem and vitamin B12", MICROBIOLOGY, vol. 14, no. 10, 1998, pages 2759 - 2769, XP008090912 *
PANDHER K.: "Identification of immunogenic, surface-exposed outer membrane proteins of Pasteurella haemolytica serotype 1", VETERINARY MICROBIOLOGY, vol. 65, 12 March 1998 (1998-03-12), pages 215 - 226, XP008092006 *
SHOBERG R.J.: "Identification of a Highly Cross-Reactive Outer Surface Protein B Epitope among Diverse Geographic Isolates of Borrelia ssp. Causing Lyme Disease", JOURNAL CLINICAL MICROBIOLOGY, vol. 32, no. 2, February 1994 (1994-02-01), pages 489 - 500, XP008092790 *
TURNER D.P.: "Autotransported Serine Protease A of Neisseria meningitidis: an Immunogenic, Surface-Exposed Outer Membrane, and Secreted Protein", INFECTION AND IMMUNITY, vol. 70, no. 8, August 2002 (2002-08-01), pages 4447 - 4461, XP002442124 *

Also Published As

Publication number Publication date
WO2003006672A2 (fr) 2003-01-23
AU2002316619A1 (en) 2003-01-29
AU2002316619A8 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
AU2002305450A1 (en) Proteomimetic compounds and methods
WO1999054340A8 (fr) Reduction d'endotoxines dans la purification d'acides nucleiques
WO2003016475A3 (fr) Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2004022701A3 (fr) Amplification exponentielle d'acides nucleiques au moyen d'agents de croisement specifique favorable
WO2005082399A3 (fr) Traitement d'infections bacteriennes
WO2003011898A3 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2006116609A3 (fr) Procedes permettant de traiter les maladies des neurones moteurs peripheriques et compositions associees
AU2002358390A1 (en) Novel compounds
WO2007010080A3 (fr) Nouveaux dendrimeres carbosilanes, leur preparation et leur utilisation
WO2004029072A3 (fr) Molecules interagissant avec prpsc et utilisations associees
WO2004098536A3 (fr) Activite antivirale de peptides cathelicidiniques
EP3939599A3 (fr) Compositions à base de silicate et procédés de traitement
WO2006116380A3 (fr) Fraction plasmique ou serique pour traitement ou prevention des infections bacteriennes
WO2003006672A3 (fr) Anticorps d'acide nucleique antimicrobien, materiaux et procedes de fabrication et d'utilisation correspondants
WO2004067563A8 (fr) Inhibiteurs de peptidique de toxines derivees de ll-37
BR0309279A (pt) Macromoléculas em multicamadas e métodos para uso das mesmas
WO2005030131A3 (fr) Composes de bis-quinazoline pour le traitement des infections bacteriennes
WO2001040313A3 (fr) Proteines immunoregulatrices felines, molecules d'acide nucleique et leurs utilisations
WO2005013898A3 (fr) Nouvelles cibles et compositions destinees a etre utilisees dans la decontamination, l'immunoprophylaxie et le traitement post-exposition contre l'anthrax
WO2004110367A3 (fr) Proteines sdr du staphylocoque capitis et utilisation associee dans la prevention et le traitement d'infections
WO2005030981A3 (fr) Populations homogenes de molecules
WO2004020591A3 (fr) Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides
WO2005011587A3 (fr) Chalaropsis lysozyme proteine et son procede d'utilisation dans des applications anti-bacteriennes
WO2003044047A3 (fr) Genes de virulence, proteines, et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载